RESUMEN
The synthesis of two series of 4'-aza-carbocyclic nucleosides are described in which the 4'-substituent is either a reversed amide, relative to the carboxamide of NECA, or an N-bonded heterocycle. Using established purine substitution patterns, potent and selective examples of agonists of the human adenosine A(2A) receptor have been identified from both series. The propionamides 14-18 and the 4-hydroxymethylpyrazole 32 were determined to be the most potent and selective examples from the 4'-reversed amide and 4'-N-bonded heterocyclic series, respectively.
Asunto(s)
Agonistas del Receptor de Adenosina A2 , Compuestos Aza/síntesis química , Ácidos Carboxílicos/síntesis química , Nucleósidos/síntesis química , Nucleótidos de Pirimidina/síntesis química , Animales , Compuestos Aza/metabolismo , Compuestos Aza/farmacología , Células CHO , Ácidos Carboxílicos/metabolismo , Ácidos Carboxílicos/farmacología , Cricetinae , Cricetulus , Evaluación Preclínica de Medicamentos/métodos , Humanos , Nucleósidos/metabolismo , Nucleósidos/farmacología , Nucleótidos de Pirimidina/metabolismo , Nucleótidos de Pirimidina/farmacología , Ratas , Receptor de Adenosina A2A/metabolismoRESUMEN
Here, we describe the preclinical pharmacological profile of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel, chirally pure inhaled beta(2) adrenoceptor agonist, in comparison with marketed drugs. Indacaterol is close to a full agonist at the human beta(2) adrenoceptor (E(max) = 73 +/- 1% of the maximal effect of isoprenaline; pEC(50) = 8.06 +/- 0.02), whereas salmeterol displays only partial efficacy (38 +/- 1%). The functional selectivity profile of indacaterol over beta(1) human adrenoceptors is similar to that of formoterol, whereas its beta(3) adrenoceptor selectivity profile is similar to that of formoterol and salbutamol. In isolated superfused guinea pig trachea, indacaterol has a fast onset of action (30 +/- 4 min) similar to formoterol and salbutamol, and a long duration of action (529 +/- 99 min) comparable with salmeterol. In the conscious guinea pig, when given intratracheally as a dry powder, indacaterol inhibits 5-hydroxytryptamine-induced bronchoconstriction for at least 24 h, whereas salmeterol, formoterol, and salbutamol have durations of action of 12, 4, and 2 h, respectively. When given via nebulization to anesthetized rhesus monkeys, all of the compounds dose-dependently inhibit methacholine-induced bronchoconstriction, although indacaterol produces the most prolonged bronchoprotective effect and induces the lowest increase in heart rate for a similar degree of antibronchoconstrictor activity. In conclusion, the preclinical profile of indacaterol suggests that this compound has a superior duration of action compatible with once-daily dosing in human, together with a fast onset of action and an improved cardiovascular safety profile over marketed inhaled beta(2) adrenoceptor agonists.
Asunto(s)
Agonistas de Receptores Adrenérgicos beta 2 , Agonistas Adrenérgicos beta/farmacología , Broncoconstricción/efectos de los fármacos , Broncodilatadores/farmacología , Indanos/farmacología , Quinolonas/farmacología , Administración por Inhalación , Agonistas Adrenérgicos beta/administración & dosificación , Agonistas Adrenérgicos beta/efectos adversos , Animales , Broncodilatadores/administración & dosificación , Broncodilatadores/efectos adversos , Células Cultivadas , Clonación Molecular , Cricetinae , Cricetulus , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Cobayas , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Indanos/administración & dosificación , Indanos/efectos adversos , Macaca mulatta , Masculino , Ovario/citología , Quinolonas/administración & dosificación , Quinolonas/efectos adversos , Taquifilaxis , Factores de TiempoRESUMEN
Combinatorial chemistry technology has enabled the synthesis of large, targeted libraries consisting of a much higher ratio of pharmacologically active compounds than traditional compound archives. This has resulted in a higher number of compounds requiring follow-up characterisation in full 50% inhibitory concentration (IC50) curves after the preliminary screen. The aim of this study was to develop a new assay format and analysis protocol for IC50 determination from the minimum number of data points so that more information could be derived from a primary inhibition screen. Data points from existing 10-point IC50 curves were used retrospectively to test the accuracy of IC50 predictions derived from just one or two compound concentrations. Regression analysis showed that both methods were useful, although, as expected, two compound concentrations gave more accurate IC50 predictions. A final experimental data set comparing IC50 values derived from a two- and 10- point assay format gave highly comparable data (r2 = 0.89). This study shows that it is possible to generate IC50 values from an appropriately designed primary inhibition screen using two compound concentrations, reducing the requirement for follow-up IC50 determinations.